High Sensitivity C Reactive Protein: An Adjunct Diagnosis in Ruling Out Pediatric Tuberculosis
- 1 Downloads
The utility of C-reactive protein (CRP) as a marker of disease severity, therapeutic response and prognosis in tuberculosis has been suggested. This study aims to determine the levels of high sensitivity CRP (hs CRP) among the pediatric tuberculosis cases. A case control study was conducted on 60 clinically diagnosed (clinical findings and radiography and/or contact history and/or Mantoux test) or microbiologically confirmed (smear and/or culture and/or Cartridge based Nucleic Acid Amplification test positive) pediatric tuberculosis cases ≤ 12 years. hs CRP levels were estimated in the cases and healthy controls using ELISA. Median levels of serum hs CRP were significantly higher in pediatric tuberculosis cases (25 mg/l) as compared to controls (0.530 mg/l). No significant correlation was found with age, gender, site of tuberculosis or presence of dissemination. Lower levels were found with palpable lymphadenopathy. Levels were not significantly different between microbiologically confirmed cases and those who were negative by one or more of the microbiological tests of staining, culture and cartridge based nucleic acid amplification test. hs CRP can be used in diagnostic algorithms of pediatric tuberculosis to rule out tuberculosis. Further studies could help in determining the prognostic and therapeutic response of hs CRP among children leading to better management.
Keywordshs CRP Pediatric Tuberculosis Diagnosis
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organisation; 2017. Available from: http://www.who.int/tb/publications/global_report/MainText_13Nov2017.pdf?ua=1. Accessed 6 Mar 2018.
- 7.Zumla A, Wallis R, Doherty M, Klein N, Parida S, Olesen O, et al. Joint TDR/EC expert consultation on biomarkers in tuberculosis. Geneva: World Health Organization; 2008.Google Scholar
- 12.Kumar M, Swati, Verma M. Prognostic value of C-reactive protein in pediatric tubercular patients on ATT. IOSR J Dent Med Sci. 2016;15(6):52–7.Google Scholar
- 14.Central TB Division, Government of India. Revised national tuberculosis control programme: technical and operational guidelines for TB control in India. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2016. p. 1–269.Google Scholar
- 15.Singh V, Mahto D. Antitubercular drugs and RNTCP guidelines for childhood tuberculosis. In: Gupta P, Menon PSN, Ramji S, Lodha R, editors. PG Textbook of pediatrics: infections and systemic disorders. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2018. p. 1348.Google Scholar
- 16.Forbes BA, Sahm DF, Weissfeld AS. Mycobacteria and other bacteria with unusual growth requirements. In: Forbes BA, Sahn DF, Weissfeld AS, editors. Bailey & Scott’s diagnostic microbiology. 13th ed. Missouri: Mosby Elsevier Inc; 2014. p. 484–512.Google Scholar
- 17.Central TB Division, Government of India. Revised National TB Control Programme Training Manual for Mycobacterium tuberculosis culture and drug susceptibility testing. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare; 2009. Available from: http://www.tbcindia.nic.in/showfile.php?lid=2991. Accessed 3 Oct 2017.